|
|
NOVARTIS: Novartis receives FDA approvable letter fo for Trileptal.
- Article from:
-
M2 Presswire
- Article date:
-
September 30, 1999
|
Copyright informationCOPYRIGHT 1999 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-30 September 1999-NOVARTIS: Novartis receives FDA approvable letter for Trileptal (C)1994-99 M2 COMMUNICATIONS LTD
RDATE:270999
Basel -- Novartis announced today that it has received an approvable letter from the US Food and Drug Administration (FDA) for Trileptal (oxcarbazepine tablets), an anti-epileptic drug for the treatment of partial seizures as adjunctive or monotherapy in adults and as adjunctive therapy in pediatric patients. An approvable letter usually represents the final step before a product receives FDA clearance for marketing in the US.
"Trileptal is an important addition to therapy options for epilepsy because of its effectiveness ...